Cargando…

Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort

INTRODUCTION: To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurv...

Descripción completa

Detalles Bibliográficos
Autores principales: Sendi, Parham, Thierstein, Marc, Widmer, Nadja, Babongo Bosombo, Flora, Büchi, Annina Elisabeth, Güntensperger, Dominik, Blum, Manuel Raphael, Baldan, Rossella, Tinguely, Caroline, Gahl, Brigitta, Heg, Dik, Theel, Elitza S., Berbari, Elie, Endimiani, Andrea, Gowland, Peter, Niederhauser, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168549/
https://www.ncbi.nlm.nih.gov/pubmed/35759237
http://dx.doi.org/10.1002/iid3.640
_version_ 1784721034744692736
author Sendi, Parham
Thierstein, Marc
Widmer, Nadja
Babongo Bosombo, Flora
Büchi, Annina Elisabeth
Güntensperger, Dominik
Blum, Manuel Raphael
Baldan, Rossella
Tinguely, Caroline
Gahl, Brigitta
Heg, Dik
Theel, Elitza S.
Berbari, Elie
Endimiani, Andrea
Gowland, Peter
Niederhauser, Christoph
author_facet Sendi, Parham
Thierstein, Marc
Widmer, Nadja
Babongo Bosombo, Flora
Büchi, Annina Elisabeth
Güntensperger, Dominik
Blum, Manuel Raphael
Baldan, Rossella
Tinguely, Caroline
Gahl, Brigitta
Heg, Dik
Theel, Elitza S.
Berbari, Elie
Endimiani, Andrea
Gowland, Peter
Niederhauser, Christoph
author_sort Sendi, Parham
collection PubMed
description INTRODUCTION: To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign. METHODS: The cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires. RESULTS: The mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose. CONCLUSION: These data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals.
format Online
Article
Text
id pubmed-9168549
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91685492022-06-07 Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort Sendi, Parham Thierstein, Marc Widmer, Nadja Babongo Bosombo, Flora Büchi, Annina Elisabeth Güntensperger, Dominik Blum, Manuel Raphael Baldan, Rossella Tinguely, Caroline Gahl, Brigitta Heg, Dik Theel, Elitza S. Berbari, Elie Endimiani, Andrea Gowland, Peter Niederhauser, Christoph Immun Inflamm Dis Original Articles INTRODUCTION: To assess the risk for COVID‐19 of police officers, we are studying the seroprevalence in a cohort. The baseline cross‐sectional investigation was performed before a vaccination campaign in January/February 2021, and demonstrated a seroprevalence of 12.9%. Here, we demonstrate serosurveillance results after a vaccination campaign. METHODS: The cohort consists of 1022 study participants. The 3‐ and 6‐month follow‐up visits were performed in April/May and September 2021. Data on infection and vaccination rates were obtained via measuring antibodies to the nucleocapsid protein and spike protein and online questionnaires. RESULTS: The mean age of the population was 41 (SD 8.8) years, 72% were male and 76% had no comorbidity. Seroconversion was identified in 1.05% of the study population at the 3‐month visit and in 0.73% at the 6‐month visit, resulting in an infection rate of 1.8% over a time period of 6 months. In comparison, the infection rate in the general population over the same time period was higher (3.18%, p = .018). At the 6‐month visit, 77.8% of participants reported being vaccinated once and 70.5% twice; 81% had an anti‐S antibody titer of >250 U/ml and 87.1% of ≥2 U/ml. No significant association between infection and job role within the department, working region, or years of experience in the job was found. Anti‐spike antibody titers of vaccinated study participants showed a calculated decreasing trend 150–200 days after the second vaccine dose. CONCLUSION: These data confirm the value of the vaccination campaign in an exposed group other than healthcare professionals. John Wiley and Sons Inc. 2022-06-06 /pmc/articles/PMC9168549/ /pubmed/35759237 http://dx.doi.org/10.1002/iid3.640 Text en © 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Sendi, Parham
Thierstein, Marc
Widmer, Nadja
Babongo Bosombo, Flora
Büchi, Annina Elisabeth
Güntensperger, Dominik
Blum, Manuel Raphael
Baldan, Rossella
Tinguely, Caroline
Gahl, Brigitta
Heg, Dik
Theel, Elitza S.
Berbari, Elie
Endimiani, Andrea
Gowland, Peter
Niederhauser, Christoph
Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
title Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
title_full Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
title_fullStr Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
title_full_unstemmed Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
title_short Serosurveillance after a COVID‐19 vaccine campaign in a Swiss police cohort
title_sort serosurveillance after a covid‐19 vaccine campaign in a swiss police cohort
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168549/
https://www.ncbi.nlm.nih.gov/pubmed/35759237
http://dx.doi.org/10.1002/iid3.640
work_keys_str_mv AT sendiparham serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT thiersteinmarc serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT widmernadja serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT babongobosomboflora serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT buchianninaelisabeth serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT guntenspergerdominik serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT blummanuelraphael serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT baldanrossella serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT tinguelycaroline serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT gahlbrigitta serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT hegdik serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT theelelitzas serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT berbarielie serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT endimianiandrea serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT gowlandpeter serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT niederhauserchristoph serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort
AT serosurveillanceafteracovid19vaccinecampaigninaswisspolicecohort